Venus Remedies scrip surges over 13% on patent win

Shares of pharmaceutical firm Venus Remedies Ltd today surged over 13 per cent after the company secured Indian product patent for an antibiotic research product, Vancoplus.
The stock soared 13.23 per cent to settle at Rs 184.45 on the BSE. During the day, it climbed 18.41 per cent to Rs 192.90.
At the NSE, the stock advanced by 11.98 per cent to end at Rs 182.80.
On the volume front, 4.91 lakh shares of the company changed hands at the BSE and over 15 lakh shares were traded at the NSE during the day.
Venus Remedies Ltd today said it has received Indian product patent for its antibiotic research product Vancoplus.

The Indian Patent Office (IPO) granted the licence which is valid till 2025, said Venus.
Vancoplus is a novel antibiotic entity that is highly effective against the notorious MRSA (methicillin-resistant staphylococcus aureus) bacterial strain and multi-drug resistant microbes primarily responsible for causing infections like meningitis, pneumonia, typhoid, septicemia, urinary tract ailments and skin diseases, the company said.